Dexrazoxane
Iron chelator / Ferroptosis inhibitor / Dexrazoxane is an iron chelator that has been used as a cardioprotective agent employed during chemotherapy with anthraquinone drugs such as daunorubicin or doxorubicin.1 More recently it has been shown to inhibit ferroptosis. It inhibited ferroptosis in a cyclophophosphamide-induced cystitis model2 as well as in doxorubicin-induced cardiomyopathy3,4.
Biochemicals & reagents
24584-09-6
ICRF-187; NSC169780
1 Jones et al. (2008), Utility of dexrazoxane for the reduction of anthracycline-induced cardiotoxicity; Expert Rev. Cardiovasc. Ther., 6 1311 2 Mao et al. (2023), Ferroptosis contributes to cyclophosphamide-induced hemorrhagic cystitis; Chem. Biol. Interact., 384 110701 3 Zhang et al. (2021), Protective Effects of Dexrazoxane on Rat Ferroptosis in Doxorubicin-Induced Cardiomyopathy Through Regulating HMGB1; Front. Cardiovasc. Med., 8 685434 4 Huang et al. (2024), Pharmacological activation of GPX4 ameliorates doxorubicin-induced cardiomyopathy; Redox Biol., 70 103024
RT
TARGET: Chelator; Topoisomerase -- PATHWAY: DNA synthesis; Transcription; Apoptosis inhibitor; Ferroptosis -- RESEARCH AREA: Oxidative stress; Cell death -- DISEASE AREA: Cancer; Heart disease